Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer
This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.
• Age ≥ 18 years;
• American Society of Anesthesiologists (ASA) physical status I-III;
• Body mass index (BMI) 18-30 kg/m²;
• Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection;
• Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3;
• Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities;
• No infection around the acupuncture sites;
• Voluntary written informed consent provided by the subject.